Pan-Lin Capital
VC Fund
Shanghai, China
Pan-Lin Capital is a VC fund in Shanghai focused on Health Care and Biotechnology. Panlin Capital, following the investment theme of ‘consumption upgrade driven by technology innovation’, targets the start-ups which are specialized in biotechnology and data intelligence sectors.As a venture capital corporation, Panlin Capital has became professional as well as influential in the biotechnology and data intelligence sectors.Identify the entrepreneurs among scientists.Enable the innovators among entrepreneurs。
- Total investments:
- 83
- Last investment:
- Lead investor:
- 43%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Pan-Lin Capital invests in
Stages Pan-Lin Capital invests in
Countries Pan-Lin Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.4k–$28M
- Series A
- $297k–$37M
- Series B
- $7.3M–$58M
Investment Focus
Industry
- Health Care 18 (22%)
- Biotechnology 16 (19%)
- Medical 15 (18%)
- Manufacturing 12 (14%)
- Pharmaceutical 6 (7%)
Stage
- Series A 22 (27%)
- Seed 19 (23%)
- Series B 12 (14%)
- Series C 6 (7%)
- Angel 4 (5%)
Country
- China 48 (58%)
- United States 2 (2%)
- Canada 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Li Yuhui
Founding Managing Partner, Executive Director
|
Founding Managing Partner, Executive Director | Total investments: 18 | Find email | |
Tan Huidong
Co-Founder, Partner & Supervisor
|
Co-Founder, Partner & Supervisor | Total investments: 0 | Find email | |
Xue Mengjun
Managing Partner
|
Managing Partner | Total investments: 3 | Find email | |
|
Yuheng Liu
Co-Founder & Partner
|
Co-Founder & Partner | Total investments: 1 | Find email | |
Zhongbo Wang
Vice President and Chief Financial Officer
|
Vice President and Chief Financial Officer | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Lingtai Krypton Biotechnology is an innovative corporation that specializes in the development of lncRNA drugs. | Series A / Jun 26, 2026 | ||
| Lingdong Core Optics is a high-tech firm that specializes in the design and implementation of silicon-based integrated optoelectronic chips. | Angel / Apr 30, 2026 | ||
|
UniXell Biotechnology
|
Yuesai Biotechnology is a new-generation cell therapy drug developer, focusing on the development of a new generation of cell therapy drugs. | $7.2M / Series A / Feb 11, 2026 | |
| Aerofugia is a technology company with low-altitude travel and vehicle-mounted flight as its core, and a practitioner of the new general aviation strategy under Geely Technology Group. | $144M / Series C / Feb 02, 2026 | ||
| Dishi Medical is a company that manufactures Ophthalmic Medical Devices and other micro-assisted robots supported by biotechnology. | Series A / Jan 19, 2026 | ||
|
LyncBio Therapeutics
|
$14.3M / Seed / Dec 25, 2025 | ||
| Hyperway Pharm is a pharmaceutical R&D and production enterprise with R&D as the core driving force. It adheres to the philosophy of “Hai Na Baichuan, Bocai, Changzhi, Good People, and Great Deeds”, and is committed to building a world-leading research and development platform for small molecule innovative drugs and high-end APIs. Researchand development platform for research and development platforms and high-tech barriers. Its core founding team is a special high-end talent in Chengdu, Sichuan Province, and has many Fortune 500 companies such as Bayer, Johnson & Johnson, Sanofi and Merck, as well as “Kingming Kant”. Work experience of domestic well-known pharmaceutical companies such as “Hengrui”, “Yangzijiang”, “Hai Cisco”, “Smart Chemical” and “Bite Pharmaceutical”, with rich experience in international and domestic drug development and management, and led the team. It has successively developed a number of world-class innovative drugs (which have entered clinical trials) and a number of high-end high-end generic drugs | $28.1M / Series B / Oct 22, 2025 | ||
| Libo Biotech is a cutting-edge biotechnology company dedicated to the discovery and development of innovative small molecule therapeutics that specifically target RNA. | $13.9M / Seed / Aug 11, 2025 | ||
| Suzhou Ribo Life Science is a developer of RNA interference ( RNAi ) technology designed to treat liver diseases. The company's RNA interference ( RNAi ) technology is used to develop nucleic acid therapeutic drugs and related products, enabling healthcare providers to deliver more effective pharmaceuticals to patients. | $27.9M / Series E / Jul 21, 2025 | ||
| Huarui Shuxin develops high-performance and high-reliability domestic RAID control cards in the field of core storage hardware. | Angel / Jul 08, 2025 | ||
| See all 83 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Pan-Lin Capital invest in?
Pan-Lin Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Seed stage. Most of the 83 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Pan-Lin Capital's check size?
Pan-Lin Capital typically joins rounds of $1.4k–$28M at Seed, $297k–$37M at Series A and $7.3M–$58M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Pan-Lin Capital participates in.
How do I contact Pan-Lin Capital?
Public channels for Pan-Lin Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Pan-Lin Capital?
The team at Pan-Lin Capital includes Li Yuhui (Founding Managing Partner, Executive Director), Tan Huidong (Co-Founder, Partner & Supervisor) and Xue Mengjun (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
